Lexicon Pharmaceuticals Inc

Healthcare · Biotechnology

1.90$ -1.1% vs. previous close Closing price · As of: Sep 29, 2026

Statements

Balance Sheet

Lexicon Pharmaceuticals Inc (LXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 185 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LXRX
Line item	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	22	221	240	202	284	212	219	190	369	262	258	367	431	372	274	471	655	476	437	284	418	204	137	194	229	298	185
Current Assets	13	206	166	133	172	99	106	86	265	109	170	215	282	231	135	369	532	358	322	173	338	158	89	141	177	246	102
Cash	2.0	38	23	39	82	15	22	30	23	86	101	47	282	223	129	339	521	347	311	160	36	126	64	46	22	67	34
Cash & Short-Term Investments	9.1	203	156	94	104	88	100	80	259	103	163	211	282	223	129	339	521	347	311	160	272	152	87	138	170	238	96
Receivables	3.4	2.8	4.5	5.1	6.6	6.4	2.6	1.2	1.8	0.6	0.8	0.7	0.4	1.4	0.8	1.0	0.9	7.5	4.8	5.9	57	0.4	0.0	0.0	1.0	3.5	2.4
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	-4.1	0.0	0.0	4.8	0.0	0.0	1.9	4.7	4.2	0.0	–	0.0	0.4	0.2	0.3
Property, Plant & Equipment	–	14	27	37	84	85	85	78	71	65	59	53	46	43	41	1.1	21	19	18	16	14	0.3	1.2	2.1	–	–	–
Goodwill	–	–	26	26	26	26	26	26	26	26	26	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45
Intangible Assets	–	–	5.4	30	29	28	26	26	26	26	26	54	54	54	54	53	53	53	52	50	20	–	–	–	–	–	–
Total Liabilities	14	13	22	32	118	90	133	105	83	66	94	120	133	105	104	187	369	318	384	311	301	47	23	77	136	152	77
Current Liabilities	11	11	19	21	32	39	57	46	35	21	51	11	25	18	19	45	123	165	124	37	65	47	22	23	32	45	21
Short-Term Debt	9.4	1.0	–	–	–	4.7	4.8	0.8	0.9	1.0	38	1.1	25	-7.3	-6.0	10	-23	-16	2.1	-14	12	12	1.1	1.3	1.3	1.2	6.2
Accounts Payable	1.2	2.5	3.2	4.4	5.9	7.6	6.9	6.5	7.3	7.9	5.9	3.2	6.0	7.7	9.7	13	20	53	39	12	12	5.5	9.2	10	14	15	3.1
Long-Term Debt	–	1.8	–	4.0	56	33	32	31	30	30	28	27	23	22	20	88	104	85	232	244	234	–	–	49	100	100	49
Shareholders' Equity	8.2	208	218	170	166	122	86	86	256	186	164	247	298	267	-1,004	284	286	157	52	-1,472	117	156	114	117	93	146	108
Retained Earnings	-29	-55	-90	-150	-214	-261	-297	-352	-411	-487	-570	-673	-790	-900	-1,004	-1,104	-1,109	-1,250	-1,381	-1,472	-1,341	-1,400	-1,488	-1,590	-1,767	-1,967	-2,018
Shares Outstanding	3.5	5.9	7.2	7.5	8.1	9.0	9.1	9.6	14	20	21	43	49	70	73	76	104	104	105	106	117	111	146	166	221	320	363

Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings